Therapeutic potential of PIMSR, a novel CB1 receptor neutral antagonist, for cocaine use disorder: evidence from preclinical research

Cannabinoid CB1 receptors (CB1Rs) have been major targets in medication development for the treatment of substance use disorders. However, clinical trials with rimonabant, a CB1R antagonist/inverse agonist, failed due to severe side effects. Here, we evaluated the therapeutic potential of PIMSR, a n...

Descripción completa

Detalles Bibliográficos
Autores principales: Galaj, Ewa, Hempel, Briana, Moore, Allamar, Klein, Benjamin, Bi, Guo-Hua, Gardner, Eliot L., Seltzman, Herbert H., Xi, Zheng-Xiong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293959/
https://www.ncbi.nlm.nih.gov/pubmed/35851573
http://dx.doi.org/10.1038/s41398-022-02059-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293959/
https://www.ncbi.nlm.nih.gov/pubmed/35851573
http://dx.doi.org/10.1038/s41398-022-02059-w

Ejemplares similares